Aktuellt
SENASTE
Redeye comments on publication of a case report from Fluoguide’s ongoing phase I/II trial. The case report shows that FG001 appeared helpful in surgical guidance in a meningioma patient who was wrongly diagnosed with high-grade glioma pre-surgery. Fluoguide had already announced inclusion of two non-high-grade glioma patients earlier, and we judge the report requires cautious interpretation given it only features a single patient. Still, the data strengthen our conviction in FG001’s applicability outside of high-grade glioma. We include meningioma in our sales model and raise our Base Case.
LÄS MER
